ABUS Quote, Trading Chart, Arbutus Biopharma Corporation
home / stock / abus / abus quote
$3.30 Last:
5.1% Change Percent:
$3.2 Open:
$3.30 Previous Close:
$3.3 High:
$2.91 Low:
3,751,329 Volume:
03/05/2021 04:55:13 pm Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2021-03-05 | 3.2 | 3.3 | 3.3 | 2.91 | 3,751,329 |
| 2021-03-04 | 3.57 | 3.14 | 3.6 | 3.01 | 4,423,673 |
| 2021-03-03 | 3.8452 | 3.64 | 3.88 | 3.6201 | 1,735,259 |
| 2021-03-02 | 3.88 | 3.83 | 3.91 | 3.7901 | 1,315,818 |
| 2021-03-01 | 3.9 | 3.84 | 3.98 | 3.74 | 2,066,048 |
| 2021-02-26 | 3.94 | 3.75 | 3.945 | 3.66 | 2,408,799 |
| 2021-02-25 | 4.31 | 3.81 | 4.37 | 3.775 | 3,309,419 |
| 2021-02-24 | 3.93 | 4.42 | 4.49 | 3.9 | 3,699,674 |
| 2021-02-23 | 4.16 | 3.83 | 4.18 | 3.64 | 3,870,899 |
| 2021-02-22 | 4.4 | 4.29 | 4.555 | 4.25 | 2,373,845 |
| 2021-02-19 | 4.34 | 4.39 | 4.65 | 4.3 | 2,318,344 |
| 2021-02-18 | 4.37 | 4.28 | 4.43 | 4.22 | 1,832,488 |
| 2021-02-17 | 4.5 | 4.41 | 4.5811 | 4.28 | 2,033,058 |
| 2021-02-16 | 4.47 | 4.49 | 4.6401 | 4.36 | 2,317,686 |
| 2021-02-15 | 4.38 | 4.33 | 4.4148 | 4.235 | 1,777,428 |
| 2021-02-12 | 4.38 | 4.33 | 4.4148 | 4.235 | 1,771,333 |
| 2021-02-11 | 4.41 | 4.38 | 4.61 | 4.15 | 2,648,179 |
| 2021-02-10 | 4.55 | 4.43 | 4.73 | 4.27 | 3,340,894 |
| 2021-02-09 | 5 | 4.47 | 5.14 | 4.45 | 6,914,118 |
| 2021-02-08 | 4.29 | 4.84 | 4.89 | 4.23 | 11,413,083 |
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
News, Short Squeeze, Breakout and More Instantly...
-
Image source: The Motley Fool. Arbutus Biopharma (NASDAQ: ABUS) Q4 2020 Earnings Call Mar 04, 2021 , 8:45 a.m. ET Operator Continue reading For further details see: Arbutus Biopharma (ABUS) Q4 2020 Earnings Call Transcript
-
AB-729, Arbutus’ proprietary subcutaneously delivered RNAi agent, demonstrates robust and continuous declines in hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B (HBV) with favorable safety and tolerability data Reductions in HBsAg seen i...
-
WARMINSTER, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (includi...